Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-10-07
1999-10-26
Kunz, Gary L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 56, 514824, A61K 3170, A61K 31725, C08L 510
Patent
active
059729031
ABSTRACT:
This invention relates to a method of promoting growth of new blood vessels, i.e., angiogenesis, by coadministration of an adenosine receptor agonist, e.g., adenosine, and heparin over a period of several days. In particular, this invention is applicable to promoting angiogenesis to improve collateral coronary circulation in patients suffering from myocardial infarction.
REFERENCES:
patent: 3819612 (1974-06-01), Imai et al.
patent: 3819613 (1974-06-01), Marumoto et al.
patent: 4738954 (1988-04-01), Hamilton et al.
patent: 4868160 (1989-09-01), Hamilton et al.
patent: 4886786 (1989-12-01), Lindstrom et al.
patent: 4954504 (1990-09-01), Chen et al.
patent: 5034381 (1991-07-01), Hutchison et al.
patent: 5063233 (1991-11-01), Chen et al.
patent: 5104859 (1992-04-01), Sollevi
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5231086 (1993-07-01), Sollevi
patent: 5236908 (1993-08-01), Gruber et al.
patent: 5275812 (1994-01-01), Gold et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5449665 (1995-09-01), Sollevi
patent: 5462752 (1995-10-01), Chao et al.
patent: 5529986 (1996-06-01), Larsson et al.
patent: 5534504 (1996-07-01), Sollevi
patent: 5593688 (1997-01-01), Baldeschwieier
patent: 5593875 (1997-01-01), Wurm et al.
patent: 5731296 (1998-03-01), Sollevi
Bautovich, G., et a., "Detection of Deep Venous Thrombi and Pulmonary Embolus with Technetium-99m-DD-3B6/22 Anti-fibrin Monoclonal Antibody Fab' Fragment," J. Nucl. Med. vol. 35, pp. 195-202 (1994).
Buckley and Sorkin, "Enoxaparin: A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders," Drugs, vol. 44, pp. 465-497 (1992).
Japanese Abstract: JP01 187083 Nippon Mining Co. LTD, Jul. 1989.
Chan, Sammy Y., "Comparison of Maximal Myocardial Blood Flow During Adenosine Infusion With That of Intravenous Dipyridamole in Normal Men," JACC, vol. 20, No. 4, pp. 979-985 (1992).
Chiarugi, V., "Cooperation of Heparin With Other Angiogenetic Effectors," International Journal of Tissue Reactions, VII(2), pp. 129-133 (1986).
Faulds, Diana, "Adenosine An Evaluation of its Use in Cardiac Diagnostic Procedures, and in the Treatment of Paroxysmal Supraventricular Tachycardia," Drugs, pp. 596-624 (1991).
Hara, Toshihiko, "Quantitative measurement of regional myocardial blood flow in patients with coronary artery disease by intravenous injection of .sup.13 N-ammonia in positron emission tomography," Nuclear Medicine, pp. 231-235 (1990).
Hutchins, Gary D., "Positron Emission Tomography to Quantitate Myocardial Perfusion," American Journal of Cardiac Imaging, vol. 7, No. 4, pp. 283-293 (1993).
Hutchins, Gary D., "Noninvasive Quantification of Regional Blood Flow in the Human Heart Using N-13 Ammonia and Dynamic Positron Emission Tomographic Imaging," JACC, vol. 15, No. 5, pp. 1032-1042 (1990).
Luria, Myron H., "Cardiovascular Risk Factor Clustering and Ratio of Total Cholesterol to High-Density Lipoprotein Cholesterol in Angiographically Documented Coronary Artery Disease," American Journal of Cardiology, vol. 67, pp. 31-36 (1991).
McAuslan, B.R., "Angiogenic Factors and Their Assay: Activity of Formyl Methionyl Leucyl Phenylalanine, Adenosine Diphosphate, Heparin, Copper, and Bovine Endothelium Stimulating Factor," Microvascular Research, pp. 323-338 (1983).
Schelbert, M.D., Heinrich R., "Consideration of Measurements of Myocardial Blood Flow with Positron-Emission Tomography," Investigative Radiology, vol. 28, Supp. 4, pp. S47-S55 (1993).
Soufer, M.D., Robert, et al., "Positron Emission Tomography And the Quantitative Assessment of Regional Myocardial Blood Flow," JACC, vol. 15, No. 1, pp. 128-130 (1990).
Symons, J. David, "Repeated Dipyridamole Administration Enhances Collateral-Dependent Flow and Regional Function During Exercise," Department of Internal Medicine, pp. 503-513 (1992).
Terrell, Grace E., "Indirect Angiogenic Agents Do Not Release Fibroblast Growth Factors From Extracellular Matrix," Matrix, vol. 11, pp. 108-114 (1991).
Tucker, K.J., "The applications of adenosine in noninvasive cardiac imaging," Herz 17, pp. 122-136 (1992).
Unger, Ellis F., "Heparin promotes the formation of extracardiac to coronary anastomoses in a canine model," American Journal of Physiology, vol. 260, No. 5, pp. H1625-H1634 (1991).
Valk, P.E., "Quantitative Assessment of Reversible Myocardial Ischemia by Dipyridamole Perfusion," The Journal of Nuclear Medicine, vol. 30, No. 5, pp. 760 (1989).
Araie, E. et al., "Heparin exercise treatment following percutaneous transluminal coronary angioplasty in a patient with effort angina," Heart and Vessels, vol. 6, pp. 181-183 (1991).
Ely, S.W. et al., "Protective effects of adensoine in myocardial ischemia," Circulation, vol. 85, No. 3, pp. 893-904 (1992).
Ethier, M.F. et al., "Adenosine stimulates proliferation of human endothelial cells in culture," Am. J. Physiol., pp. H131-H138, (1993).
Fujita, M. et al., "Longterm efficacy of heparin exercise treatment for patients with chronic effort angina; evaluation by exercise T1-201 myocardial scintigraphy," Int. J. Cardiol., vol. 40, pp. 51-56, (1993).
Fujita, M. et a., "Comparative effect of heparin treatment with and without strenuous exercise on treadmill capacity in patients with stable effort angina," Am. Heart Journal., vol. 122, pp. 453-457, (1991).
Melandri, G. et al., "Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-bloind, randomized,placebo-controlled trial," Circulation, vol. 88, pp. 2517-2523, (1993).
Norrby, K. et al., "Heparin enhances angiogenesis by a systemic mode of action," Int. J. Exp. Pathol. vol. 73, pp. 147-155, (1992).
Sasayama, S. et al., "Recent insights into coronary collateral circulation," Circulation, vol. 85, pp. 1197-1204, (1992).
Quyyumi, A. A. et al., "Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study." J. Am. Coll. Cardiol., vol. 22, No. 3, pp. 635-641, (1992).
Norrby et al. Int. J. Exp. Physiol. 73:147, 1992.
Ethier. et al. Am. J. Physiol. H131, 1993.
Barron Hal V.
Botvinick Elias
Kunz Gary L.
Regents of the University of California Corporation
LandOfFree
Method for promoting angiogenesis using heparin and adenosine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for promoting angiogenesis using heparin and adenosine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for promoting angiogenesis using heparin and adenosine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-764570